Inicio › Linfoma difuso de células B grandes › Texas

Ensayos clínicos de Linfoma difuso de células B grandes en Texas

29 estudios sobre Linfoma difuso de células B grandes buscan participantes en Texas.

Ciudades en Texas

Texto oficial del estudio (inglés)

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

University Hospital System, San Antonio
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06977711

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Md Anderson Cancer Center, Houston

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05006716

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Texas Oncology - West Texas ( Site 8008), Amarillo
Texas Oncology - Central/South Texas ( Site 8006), Austin
UT Southwestern Medical Center ( Site 0190), Dallas
y 2 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06890884

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Texas Oncology - DFW ( Site 8000), Dallas
Houston Methodist Cancer Center ( Site 0154), Houston
Joe Arrington Cancer Research and Treatment Center ( Site 0183), Lubbock
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06717347

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Texas Oncology - DFW (Sammons CC), Dallas
Baylor College of Medicine, Houston

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07226843

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

University of Texas Southwestern, Dallas
MD Anderson Cancer Center, Houston

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07101328

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

University of Texas MD Anderson Cancer Center ( Site 1007), Houston

ReclutandoFase 1/2

6 Months – 25 Years · Todos los sexos · Actualizado el 17 sept 2026 · NCT06395103

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Md Anderson Cancer Center, Houston

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT07195916

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

Baylor Scott & White Health, Temple
Texas Oncology - Gulf Coast, The Woodlands
Texas Oncology- Northeast Texas, Tyler

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT06806033

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Texas Oncology - Central South, Austin
Texas Oncology - Dallas Fort Worth, Dallas
MD Anderson Cancer Center, Houston
y 2 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 31 ago 2026 · NCT06500273

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

MD Anderson Cancer Center, Houston

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07284433

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Baylor University Medical Center, Dallas
Texas Transplant Institute, San Antonio

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT05826535

Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)

Natera, Inc., Austin

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ago 2026 · NCT07750886

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

University of Texas MD Anderson Cancer Center, Houston

ReclutandoFase 1/2

Edades de 13 a 90 · Todos los sexos · Actualizado el 6 ago 2026 · NCT06533579

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

UT Southwestern Medical Center, Dallas

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT06116110

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

St. David's South Austin Medical Center, Austin
University of Texas Southwestern Medical Center, Fort Worth
MD Anderson Cancer Center, Houston
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 ago 2026 · NCT07188558

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

The University of TX MD Anderson Cancer Center, Houston

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 jul 2026 · NCT07424833

DALY II USA/ MB-CART2019.1 for DLBCL

UT Southwestern Medical Center, Dallas
The University of Texas MD Anderson Cancer Center, Houston
Texas Transplant Institute, San Antonio

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT04792489

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

University of Texas Southwestern Medical Center, Dallas

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jul 2026 · NCT05852717

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

MD Anderson Cancer Center, Houston

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 jul 2026 · NCT05131022

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Texas Children's Hospital, Houston

ReclutandoEstudio observacional

Edades de 0 a 38 · Todos los sexos · Actualizado el 4 jun 2026 · NCT06131801

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

University of Texas Southwestern Medical Center, Dallas

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 may 2026 · NCT06768905

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

University of Texas(UT) Southwestern-Children's Medical Center, Dallas

ReclutandoFase 1/2

Edades de 12 a 95 · Todos los sexos · Actualizado el 15 abr 2026 · NCT04329728

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

NEXT Oncology, Austin, TX 78758
NEXT Oncology, San Antonio

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 abr 2026 · NCT06451497

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

MD Anderson Cancer Center, Houston

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 20 mar 2026 · NCT04830137

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Ben Taub General Hospital, Houston
University of Texas Health Science Center at San Antonio, San Antonio

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 20 oct 2025 · NCT05890352

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

University of Texas Southwestern Medical Center, Dallas

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2025 · NCT05780034

A Study of NX-1607 in Adults With Advanced Malignancies

MD Anderson Cancer Center, Houston

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2025 · NCT05107674

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

UT Southwestern Medical Center, Dallas

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 ago 2022 · NCT04502394

De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.